Treatment Clinical Trials for Multiple Myeloma

Clinical trials are research studies that involve people. The clinical trials on this list are for multiple myeloma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 227

  • SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

    A Phase 1 / 2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
    Location: 4 locations

  • Sotatercept, Lenalidomide or Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I trial studies the side effects and best dose of sotatercept when given together with lenalidomide or pomalidomide, and dexamethasone in treating patients with multiple myeloma that has returned (relapsed) or has not responded to treatment (refractory). Biological therapies, such as sotatercept, lenalidomide, pomalidomide, and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. Giving sotatercept together with lenalidomide or pomalidomide, and dexamethasone may also improve anemia (low blood levels of hemoglobin) and bone lesions that may occur in patients with multiple myeloma.
    Location: 4 locations

  • Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

    This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation together with sirolimus, cyclosporine, and mycophenolate mofetil before and after transplant may stop this from happening.
    Location: 3 locations

  • A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

    This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SEA-BCMA should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
    Location: 4 locations

  • APG-2575 Study of Safety, Tolerability ,PK / PD in Patients With Hematologic Malignancies

    This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.
    Location: 4 locations

  • Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Multiple Myeloma, NHL, and AML

    Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and / or biologically active doses.
    Location: 3 locations

  • Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

    First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 2 weeks.
    Location: 3 locations

  • A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma

    The purpose of this study is to determine the safety and tolerability of TAK-573 monotherapy in participants with refractory multiple myeloma (MM) and to provide a preliminary evaluation of the clinical activity of TAK-573 monotherapy in participants with refractory MM.
    Location: 3 locations

  • A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

    This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients with RRMM following 2-4 lines of prior therapy and who are refractory to lenalidomide in the last line of therapy as demonstrated by disease progression on or within 60 days of completion of the last dose of lenalidomide. Patients will receive either melflufen+dex or pomalidomide+dex.
    Location: 3 locations

  • Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for JNJ-64007957 and to characterize the safety and tolerability of JNJ-64007957 at the RP2Ds.
    Location: 4 locations

  • MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I trial studies the side effects and best dose of MDM2 inhibitor AMG-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back of has not responded to previous treatment. Drugs used in chemotherapy, such as MDM2 inhibitor AMG-232, carfilzomib, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 3 locations

  • Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)

    A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy.
    Location: 4 locations

  • Lenalidomide with or without Carfilzomib and Dexamethasone in Treating Patients with Multiple Myeloma after Stem-Cell Transplant

    This randomized phase III trial studies how well lenalidomide with or without carfilzomib and dexamethasone works in treating patients with multiple myeloma after stem-cell transplant. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a drug used to reduce inflammation and lower the body’s immune response. Giving lenalidomide together with carfilzomib and dexamethasone may be an effective treatment for multiple myeloma.
    Location: 3 locations

  • Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed / Refractory Cancer Indications

    This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in patients with relapsed / refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), and higher risk myelodysplastic syndrome (HR-MDS). Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results. This study is currently closed for enrollment for patients with relapsed / refractory multiple myeloma (MM), metastatic or colorectal cancer (mCRC), and metastatic castration resistant prostate cancer (mCRPC).
    Location: 3 locations

  • Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed / Refractory Hematologic Malignancies

    This study evaluates the efficacy, safety and pharmacokinetics of EDO-S101 in patients with relapsed / refractory hematologic malignancies. All patients will receive EDO-S101.
    Location: 4 locations

  • Ixazomib Citrate with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Relapse or Refractory Multiple Myeloma

    This phase I / II trial studies the side effects and best dose of clarithromycin when given together with ixazomib citrate, pomalidomide, and dexamethasone and to see how well it works in treating patients with multiple myeloma that has come back or does not respond to treatment. Biological therapies, such as clarithromycin, pomalidomide, and dexamethasone, use substances made from living organisms that may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving clarithromycin with ixazomib citrate, pomalidomide and dexamethasone may be a better treatment for patients with multiple myeloma.
    Location: 3 locations

  • A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

    Primary Objective: - Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed / refractory multiple myeloma (RRMM). - Part B: To evaluate the activity of SAR650984 (isatuximab) as assessed by overall response rate (ORR) in RRMM patients previously treated with daratumumab. Secondary Objectives: - Part A: - To determine the pharmacokinetics (PK) of SAR650984 (isatuximab) in patients with RRMM. - Part B: - To evaluate the safety of SAR650984 (isatuximab). - To evaluate the efficacy of SAR650984 (isatuximab) as assessed by duration of response (DOR), clinical benefit rate (CBR) and progression free survival (PFS). - To assess the pharmacokinetics (PK) of SAR650984 (isatuximab) and daratumumab at baseline. - To evaluate the immunogenicity of SAR650984 (isatuximab).
    Location: 4 locations

  • Isatuximab and Carfilzomib with or without Dexamethasone and Lenalidomide in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement or has not respond to previous treatment. Monoclonal antibodies, such as isatuximab, may block cancer growth in different ways by targeting certain cells. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving isatuximab and carfilzomib with or without dexamethasone and lenalidomide may be a better treatment for patients with multiple myeloma.
    Location: 3 locations

  • Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

    The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.
    Location: 3 locations

  • Selinexor, Carfilzomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor, carfilzomib, and dexamethasone may be a better treatment for multiple myeloma.
    Location: 5 locations

  • Tadalafil and Lenalidomide with or without Activated Marrow Infiltrating Lymphocytes in Treating Patients with High-Risk Multiple Myeloma Undergoing Stem Cell Transplant

    This randomized phase II trial studies how well tadalafil and lenalidomide with or without activated marrow infiltrating lymphocytes work in treating patients with multiple myeloma undergoing stem cell transplant. Activated marrow infiltrating lymphocytes are blood and bone marrow cells that are stimulated to react to certain proteins and may help to target and kill cancer cells. Tadalafil may increase the possibility of trafficking activated marrow infiltrating lymphocytes to the cancer site. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether giving tadalafil and lenalidomide is more effective with or without activated marrow infiltrating lymphocytes in treating patients with multiple myeloma.
    Location: 3 locations

  • Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase Ib / II trial studies the side effects and best dose of carfilzomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement or does not respond to treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Pomalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib together with pomalidomide and dexamethasone may kill more cancer cells.
    Location: 4 locations

  • Laboratory-Treated T Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Recurrent or Refractory B-Cell Lymphoma or Multiple Myeloma

    This phase I trial studies the side effects of laboratory-treated T cells in treating patients with B-cell chronic lymphocytic leukemia, B-cell lymphoma, or multiple myeloma that has come back or has not gone away after treatment. This study combines two different ways of fighting disease, antibodies (proteins that protect the body from bacterial and other diseases) and T cells (special infection-fighting blood cells that can kill other cells, including cancer cells). Treating the T cells in the laboratory by adding an antibody may help the T cells last longer in the body and kill more cancer cells.
    Location: 3 locations

  • To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed / Refractory Multiple Myeloma (RRMM)

    This is a 2-part study, where Part 1 will be dose-escalation phase and Part 2 will be dose expansion phase. Part 1 will first evaluate the safety and tolerability profile of 2 doses of GSK2857916, when administered in combination with approved regimens of either lenalidomide plus dexamethasone (Arm A) or bortezomib plus dexamethasone (Arm B) and will identify a recommended Phase 2 dose (RP2D) for each combination treatment (Part 1). Part 2 of the study will evaluate the clinical activity at the RP2D for GSK2857916 in combination with lenalidomide plus dexamethasone (Arm A) or bortezomib plus dexamethasone (Arm B) in additional subjects with RRMM. A total of 90 evaluable subjects will be enrolled in the study of which up to 24 will be included in Part 1 and up to 66 will be included in Part 2. Subjects receiving treatment A, may continue combination treatment until the occurrence of PD, intolerable (AEs), consent withdrawal, or death. The subjects receiving treatment B, may continue combination treatment for a total of up to 8 cycles. After 8 cycles of combination therapy, the subjects will continue treatment with GSK2857916, as monotherapy until PD, intolerable AEs, consent withdrawal, or death.
    Location: 3 locations

  • A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma

    Multicenter, open-label, phase 1a / 1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.
    Location: 2 locations